Naven Health

Overview

Naven Health is Option Care Health’s nationwide home infusion nursing platform for specialty therapy administration, manufacturer patient-support programs, and home-visit clinical services. Launched in 2023 after Option Care consolidated earlier nursing assets, Naven covers all 50 states with 1,600+ active nurses and reported 160,000+ patient visits across 130+ healthcare partners.

Naven is best read as an infusion nursing and home clinical execution layer, not as a full-service CRO, standalone reimbursement or prior-authorization vendor, or dispensing specialty pharmacy. The buyer question is whether Naven can staff and execute nursing, patient onboarding, therapy administration, and home monitoring across the states and therapy areas a program needs, alongside the hub, CRO, and specialty-pharmacy partners that own the other layers.

Infusion Capability Model

The framework below standardizes how Rx Almanac evaluates infusion capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Naven Health is evaluated as an infusion nursing and home clinical execution layer, not as a full-service CRO, standalone reimbursement or prior-authorization vendor, or dispensing specialty pharmacy.

Capability	Buyer should compare	Naven Health readout
Infusion footprint	Home coverage, ambulatory suite access, pharmacy network, chair capacity, and ability to serve the target geography.	Not the main buying reason for Naven Health; validate only if the SOW includes infusion footprint.
Clinical nursing	Nurse availability, training model, therapy-specific protocols, escalation, and continuity across home and suite settings.	Core infusion nursing. Naven positions itself around nationwide home infusion nursing for specialty therapy administration. Core patient support. Naven supports onboarding and teach-and-train programs, while broader hub ownership should be scoped separately. Documented extension. Recent public updates emphasize wraparound home clinical services beyond the infusion visit. Adjacency, not the core lane. Naven can support selected decentralized visits, but it is not a full-service CRO.
Benefits and reimbursement	Benefit investigation, prior authorization, reauthorization, appeals, patient responsibility estimates, and speed from referral to start.	Not the main buying reason for Naven Health; validate only if the SOW includes benefits and reimbursement.
Complex handling	Compounding, cold-chain logistics, drug preparation, REMS, hazardous handling, and inventory controls.	Not the main buying reason for Naven Health; validate only if the SOW includes complex handling.
Manufacturer data	Referral status, start-of-care, abandonment, adherence, clinical outcomes, and inventory / dispense visibility.	Manufacturer-facing layer. Naven can support pharma programs, but buyers should define which access and pharmacy functions sit elsewhere. Diligence item. Review Naven Connect as the operating system for referrals, scheduling, documentation, and partner reporting.
Site-of-care strategy	Ability to shift care from hospital outpatient settings to home or ambulatory infusion suites without losing clinical oversight.	Not the main buying reason for Naven Health; validate only if the SOW includes site-of-care strategy.
Specialty pharmacy adjacency	Dispensing scope, LDD access, pharmacy handoffs, and boundaries with hub and specialty pharmacy networks.	Not the main buying reason for Naven Health; validate only if the SOW includes specialty pharmacy adjacency.

Buyer Fit

• Where it fits: Manufacturers launching infused, injected, rare-disease, or high-touch specialty therapies that need national nursing, patient onboarding, or home clinical capacity.
• Less natural fit: Sponsors looking for an end-to-end CRO, full outsourced hub, payer reimbursement strategy partner, or dispensing specialty pharmacy by itself.
• Program fit: Home infusion administration, self-administration teaching, post-therapy monitoring, in-home labs, vaccine support, and selected decentralized-trial visits.
• Operating model: Clarify whether Naven is contracted directly, through Option Care Health, through a hub, or as a subcontracted clinical layer for a specialty pharmacy.
• Channel fit: Use Naven when the operational bottleneck is bedside nursing and home clinical execution, not when the main decision is LDD dispensing or payer strategy.

Differentiators

• National clinical footprint: Naven markets nationwide infusion nursing coverage, which matters when a specialty therapy cannot depend on regional nursing capacity alone.
• Parent infrastructure: Option Care Health gives Naven access to a large home-infusion operating environment, payer relationships, and specialty therapy experience.
• Naven Connect: The named workflow platform gives buyers a concrete reporting and documentation layer to diligence.
• Clinical wraparound: Public updates point to in-home labs, vaccine administration, and post-therapy monitoring, making Naven broader than a narrow infusion visit provider.
• Home-visit trial adjacency: Naven can support selected decentralized or hybrid trial tasks, but should be paired with CRO and trial-system partners when scope exceeds clinical visit execution.

RFP Questions

• Which states, therapies, and routes of administration can Naven staff with credentialed nurses today?
• How does Naven separate its work from Option Care Health dispensing, and can it serve other specialty pharmacies without channel conflict?
• Which patient onboarding, teach-and-train, adherence, and post-therapy monitoring tasks are in Naven’s standard scope?
• Which hub, specialty-pharmacy, CRM, EDC, CTMS, and manufacturer reporting feeds are already supported?
• What adverse-event, product-complaint, privacy, consent, and clinical-documentation controls govern home visits?
• How are nurse credentialing, therapy-specific training, surge capacity, and continuity of care managed by state?
• What manufacturer reporting is available for referral status, completed visits, missed visits, adverse events, and patient education?
• How are GCP training, source documentation, sample handling, monitoring access, and PI oversight handled when the program includes trial visits?
• Which functions are included in Naven’s scope versus left to a hub, specialty pharmacy, CRO, or manufacturer team?

Recent Activity

• 2026-05 - Current Naven materials emphasize 1,600+ infusion nurses across all 50 states, pharma patient-support programs, decentralized-trial nursing, and Joint Commission / state-license diligence.

• 2025: Naven reported continued specialty therapy support, patient satisfaction, and service expansion into in-home labs, vaccine administration, and post-therapy lab monitoring.

• 2024: Naven reported 160,000+ patient visits, 1,600+ active nurses, and 130+ healthcare partners in its public year-in-review materials.

• 2023: Option Care Health launched Naven as a dedicated national infusion nursing brand after consolidating earlier nursing assets.